Literature DB >> 27607403

The Relationship Between Preoperative Clinical Presentation and Quantitative Magnetic Resonance Imaging Features in Patients With Degenerative Cervical Myelopathy.

Aria Nouri1, Lindsay Tetreault2, Kristian Dalzell3, Juan J Zamorano4, Michael G Fehlings1.   

Abstract

BACKGROUND: Degenerative cervical myelopathy encompasses a group of conditions resulting in progressive spinal cord injury through static and dynamic compression. Although a constellation of changes can present on magnetic resonance imaging (MRI), the clinical significance of these findings remains a subject of controversy and discussion.
OBJECTIVE: To investigate the relationship between clinical presentation and quantitative MRI features in patients with degenerative cervical myelopathy.
METHODS: A secondary analysis of MRI and clinical data from 114 patients enrolled in a prospective, multicenter study was conducted. MRIs were assessed for maximum spinal cord compression (MSCC), maximum canal compromise (MCC), signal changes, and a signal change ratio (SCR). MRI features were compared between patients with and those without myelopathy symptoms with the use of t tests. Correlations between MRI features and duration of symptoms were assessed with the Spearman ρ.
RESULTS: Numb hands and Hoffmann sign were associated with greater MSCC ( P < .05); broad-based, unstable gait, impairment of gait, and Hoffmann sign were associated with greater MCC ( P < .05); and numb hands, Hoffmann sign, Babinski sign, lower limb spasticity, hyperreflexia, and T1 hypointensity were associated with greater SCR ( P < .05). Patients with a T2 signal hyperintensity had greater MSCC and MCC ( P < .001).
CONCLUSION: MSCC was associated with upper limb manifestations, and SCR was associated with upper limb, lower limb, and general neurological deficits. Hoffmann sign occurred more commonly in patients with a greater MSCC, MCC and SCR. The Lhermitte phenomenon presented more commonly in patients with a lower SCR and may be an early indicator of mild spinal cord involvement. Research to validate these findings is required.
Copyright © 2016 by the Congress of Neurological Surgeons

Entities:  

Keywords:  Cervical spondylotic myelopathy; Clinical presentation; Diagnosis; Imaging; Spinal cord compression

Mesh:

Year:  2017        PMID: 27607403     DOI: 10.1227/NEU.0000000000001420

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  14 in total

1.  Discrepancy between functional recovery and cutaneous silent period change in surgically treated degenerative cervical myelopathy: a prospective pilot study.

Authors:  Nobuaki Tadokoro; Katsuhito Kiyasu; Yusuke Kasai; Motohiro Kawasaki; Ryuichi Takemasa; Masahiko Ikeuchi
Journal:  Spinal Cord       Date:  2019-06-18       Impact factor: 2.772

2.  Cervical arteriosclerosis is associated with preoperative clinical symptoms in patients with cervical spondylotic myelopathy.

Authors:  Gentaro Kumagai; Kanichiro Wada; Sunao Tanaka; Toru Asari; Yasuyuki Ishibashi
Journal:  Eur Spine J       Date:  2020-11-09       Impact factor: 3.134

3.  Assessment of acute traumatic cervical spinal cord injury using conventional magnetic resonance imaging in combination with diffusion tensor imaging-tractography: a retrospective comparative study.

Authors:  Fengzhao Zhu; Yulong Wang; Xiangchuang Kong; Yuan Liu; Lian Zeng; Xirui Jing; Sheng Yao; Kaifang Chen; Lian Yang; Xiaodong Guo
Journal:  Eur Spine J       Date:  2022-05-31       Impact factor: 2.721

4.  Intensity of Intraoperative Spinal Cord Hyperechogenicity as a Novel Potential Predictive Indicator of Neurological Recovery for Degenerative Cervical Myelopathy.

Authors:  Guoliang Chen; Fuxin Wei; Jiachun Li; Liangyu Shi; Wei Zhang; Xianxiang Wang; Zuofeng Xu; Xizhe Liu; Xuenong Zou; Shaoyu Liu
Journal:  Korean J Radiol       Date:  2021-03-09       Impact factor: 3.500

5.  The Relation between Cord Signal and Clinical Outcome after Anterior Cervical Discectomy in Patients with Degenerative Cervical Disc Herniation.

Authors:  Ali Rabee Kamel Hamdan
Journal:  Asian J Neurosurg       Date:  2019 Jan-Mar

6.  Recovery priorities in degenerative cervical myelopathy: a cross-sectional survey of an international, online community of patients.

Authors:  Benjamin Davies; Oliver Mowforth; Iwan Sadler; Bizhan Aarabi; Brian Kwon; Shekar Kurpad; James S Harrop; Jefferson R Wilson; Robert Grossman; Michael G Fehlings; Mark Kotter
Journal:  BMJ Open       Date:  2019-10-10       Impact factor: 2.692

7.  Cervical Spondylotic Myelopathy: Natural Course and the Value of Diagnostic Techniques -WFNS Spine Committee Recommendations.

Authors:  Mehmet Zileli; Sachin A Borkar; Sumit Sinha; Rui Reinas; Óscar L Alves; Se-Hoon Kim; Sumeet Pawar; Bala Murali; Jutty Parthiban
Journal:  Neurospine       Date:  2019-09-30

8.  Short-term predictive potential of quantitative assessment of spinal cord impairment in patients undergoing French-door Laminoplasty for degenerative cervical myelopathy: preliminary results of an exploratory study exploiting intraoperative ultrasound data.

Authors:  Guoliang Chen; Jiachun Li; Fuxin Wei; Qiao Ji; Wenyuan Sui; Bailing Chen; Xuenong Zou; Zuofeng Xu; Xizhe Liu; Shaoyu Liu
Journal:  BMC Musculoskelet Disord       Date:  2020-05-30       Impact factor: 2.362

9.  The Impact of Older Age on Functional Recovery and Quality of Life Outcomes after Surgical Decompression for Degenerative Cervical Myelopathy: Results from an Ambispective, Propensity-Matched Analysis from the CSM-NA and CSM-I International, Multi-Center Studies.

Authors:  Jamie R F Wilson; Jetan H Badhiwala; Fan Jiang; Jefferson R Wilson; Branko Kopjar; Alexander R Vaccaro; Michael G Fehlings
Journal:  J Clin Med       Date:  2019-10-17       Impact factor: 4.241

10.  Ten-Year Surgical Outcomes and Prognostic Factors for French-Door Laminoplasty in the Treatment of Multilevel Cervical Spondylotic Myelopathy.

Authors:  Guoliang Chen; Xizhe Liu; Ningning Chen; Bailing Chen; Xuenong Zou; Fuxin Wei; Shaoyu Liu
Journal:  Biomed Res Int       Date:  2020-05-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.